AstraZeneca flop a fresh blow to cancer immunotherapy combination

LONDON (Reuters) - The concept of combining two immunotherapy drugs to fight lung cancer - not so long ago one of the hottest ideas in cancer research - has suffered a fresh blow from the failure of an AstraZeneca clinical study.